Menu Content/Inhalt
Search  
Debio 8206

Debio 8206, Pamorelin® 6 months is a luteinizing hormone releasing hormone (LHRH) agonist in development for the treatment of prostate cancer. Debiopharm recently completed a phase III study with the six month formulation. These results showed similar efficacy and safety to the already marketed 1- and 3-month formulations.

Press Releases

12-Feb-2008
Clinical Update – Decapeptyl®/Trelstar® 6-Month Formulation in Advanced Prostate Cancer
31-Oct-2007
Ipsen and Debiopharm extend their Agreement for the Exclusive Commercialization of Decapeptyl®
11-May-2005
Debiopharm announces marketing and supply agreement for Trelstar® in Canada
20-Dec-2004
Debiopharm S.A. and Rowfarma S. de R.L. de C.V. enter into an Exclusive Licensing Agreement in Mexico for two approved Urology and Endometriosis Products - Decapeptyl® Depot and Decapeptyl® LA
29-Sep-2004
Debiopharm and Watson Pharmaceuticals enter into an Exclusive Licensing Agreement for two approved urology products - Trelstar® DEPOT and Trelstar® LA
-> All Press Releases

Publications

31-Jul-2003
Comparative Efficacy of Triptorelin Pamoate and Leuprolide Acetate in Men with Advanced Prostate Cancer
31-Dec-2001
Phase II trial with triptorelin in prostatic carcinoma
30-Dec-2001
A phase II trial with New Triptorelin Sustained Release formulations in Prostatic Carcinoma
30-Dec-2000
Effects of an extended-interval Dosing Regimen of Triptorelin Depot on the Hormonal Profile of Patients with Endometriosis (prospective observational study)
30-Dec-2000
A Crossover Study of Triptorelin and Leuprorelin Acetate
-> All Publications